NEW YORK (GenomeWeb News) – Molecular diagnostics firm QuanDx announced on Thursday the closing of its Series B financing round raising $1.25 million.

Proceeds will go toward further development of its platform technology and its commercial program in oncology, genetic diseases, and infectious diseases. The Menlo Park, Calif.-based company did not disclose the names of the investors.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: epigenetic changes linked with high-altitude pulmonary edema, transcriptome profiling of maize leaf development, and more.

Stanford University researchers are studying top athletes to uncover genes linked to performance.

The UW's Wylie Burke and Dartmouth's Gilbert Welch argue that whole-genome testing may do more harm than good, and a related poll.

Differences in DNA methylation could be used to distinguish between DNA samples obtained from identical twins, researchers say.